Recent clinical trials have changed the management paradigm for diabetic macular edema (DME). There is an urgent need to identify the most effective ways of preventing retinopathy or intervening at an early, asymptomatic stage in order to preserve vision. The rise in the incidence of diabetes is a serious public health concern. Grading and screening programmes help to identify sight threatening diabetic retinopathy in the community early and facilitate timely referral to an ophthalmologist. Systemic therapies for DME target the key modifiable risk factors: metabolic and blood pressure control. There may also be a role for modification of the renin-angiotensin system and for lipid lowering agents. Improved glycemic and blood pressure control remain the most effective ways of reducing morbidity from DME. Fenofibrate also has beneficial effects, but the mechanism for this remains unclear. Multiple new treatments are in the pipeline, and these are expected to change our approach to DME for the first time in 30 years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.survophthal.2012.10.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Secretogranin III: a promising therapeutic target for intraocular neovascular lesions.
Int Ophthalmol
January 2025
Department of Ophthalmology, The Second Hospital of Jilin University, #218 Ziqiang Street, Changchun, 130041, Jilin, China.
Purpose: The purpose of this study is to investigate the role of Secretogranin III (Scg3) in the pathogenesis of intraocular neovascular diseases and assess its potential as a therapeutic target for novel treatment strategies.
Methods: A literature review was conducted to examine the expression of Scg3 in intraocular neovascular diseases. We reviewed studies on the interaction of Scg3 with its homologous receptors and its effect on endothelial cell proliferation, migration, and vascular permeability-key processes involved in angiogenesis and neovascularization.
Prediction of OCT contours of short-term response to anti-VEGF treatment for diabetic macular edema using generative adversarial networks.
Photodiagnosis Photodyn Ther
January 2025
Department of Ophthalmology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. Electronic address:
Diabetic macular edema (DME) stands as a leading cause for vision loss among the working-age population. Anti-vascular endothelial growth factor (VEGF) agents are currently recognized as the first-line treatment. However, a significant portion of patients remain insensitive to anti-VEGF, resulting in sustained visual impairment.
View Article and Find Full Text PDFChoroidal thickness and vascular density after rhegmatogenous retinal detachment.
Acta Ophthalmol
January 2025
Department of Ophthalmology, Stavanger University Hospital, Stavanger, Norway.
Purpose: To study choroidal thickness (CT) and luminal areas of choroidal vessels in the setting of fovea-off rhegmatogenous retinal detachment (RRD).
Methods: Twenty-seven eyes with RRD were prospectively studied before and after pars plana vitrectomy and SF6 tamponade, using swept-source optical coherence tomography (SS-OCT). CT was measured pre- and postoperatively both subfoveally and in attached macular areas.
A pharmacovigilance study on the safety of faricimab in real-world scenario using FDA adverse event reporting system database.
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Background: Faricimab is predominantly prescribed for conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema related to retinal vein occlusion (RVO-ME). Currently, a notable absence of large-scale, real-world studies focusing on the adverse reactions of faricimab exists.
Methods: This study assesses the side effects of faricimab by analyzing reports of adverse events (AEs) from the FDA's AE Reporting System (FAERS) database.
Evaluation of macular retinal oximetry across different levels of diabetic retinopathy: a cross sectional study.
BMC Ophthalmol
January 2025
College of Optometry, University of Houston College of Optometry, 4401 Martin Luther King Blvd, 77204-2020, Houston, TX, USA.
Background: This study evaluates retinal oxygen saturation and vessel density within the macula and correlates these measures in controls and subjects with type 2 diabetes (DM) with (DMR) and without (DMnR) retinopathy. Changes in retinal oxygen saturation have not been evaluated regionally in diabetic patients.
Methods: Data from seventy subjects (28 controls, 26 DMnR, and 16 DMR were analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!